Company / Return on Assets (ROA)
Inhibrx Biosciences, Inc. Return on Assets (ROA) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-95.6%
FY2025
5-year range
-133.5% / -78.4%
FY2023-FY2025
Trend
+28.4%
vs FY2024
Sector context
#206 of 213
Health Care
What the data says
Among 213 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 3% for return on assets (roa). Declined from -78.4% to -95.6% over the past 2 years.
Based on SEC 10-K filings.
-95.6% in FY2025.
Declined from -78.4% to -95.6% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 213This company -95.6% Sector average -24.1%
▼
-296.1% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 28.4% year-over-year.
- Currently 71.5pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -95.6% | +28.4% |
| FY2024 | -133.5% | -70.3% |
| FY2023 | -78.4% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026